239 related articles for article (PubMed ID: 34162378)
1. Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study.
Wang Y; Zhou R; Zhang X; Liu H; Shen D; Wang J
BMC Womens Health; 2021 Jun; 21(1):252. PubMed ID: 34162378
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
Xi Y; Liu G; Liu D; Jiang J; Gong R
Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
[TBL] [Abstract][Full Text] [Related]
3. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
[No Abstract] [Full Text] [Related]
5. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of fertility-sparing therapy of patients with complex atypical hyperplasia and endometrial cancer].
Morimoto C; Wang YQ; Zhou R; Wang JL
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):936-942. PubMed ID: 36241236
[TBL] [Abstract][Full Text] [Related]
7. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
8. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
9. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients.
Yang B; Xie L; Zhang H; Zhu Q; Du Y; Luo X; Chen X
J Gynecol Oncol; 2018 May; 29(3):e35. PubMed ID: 29533020
[TBL] [Abstract][Full Text] [Related]
11. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
12. [Analyze of obesity indicators and effect of fertility preservation treatment in patients with endometrial atypical hyperplasia and early endometrial cancer].
Bo LL; Wang YQ; Liu YY; Li XD; Zhou R; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2022 Oct; 57(10):767-774. PubMed ID: 36299180
[No Abstract] [Full Text] [Related]
13. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
14. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
[TBL] [Abstract][Full Text] [Related]
15. Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Ushijima K; Tsuda N; Yamagami W; Mitsuhashi A; Mikami M; Yaegashi N; Enomoto T
J Gynecol Oncol; 2023 May; 34(3):e38. PubMed ID: 36659833
[TBL] [Abstract][Full Text] [Related]
16. [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer].
Dong YT; Guan J; Yang BY; Yierfulati G; Xue Y; Chen XJ
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):729-735. PubMed ID: 38462352
[No Abstract] [Full Text] [Related]
17. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
18. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome.
Wang L; Luo X; Wang Q; Lv Q; Wu P; Liu W; Chen X
J Gynecol Oncol; 2021 Sep; 32(5):e70. PubMed ID: 34132069
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
[No Abstract] [Full Text] [Related]
20. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]